Active Pharmaceutical Market Leadership

1
Active Pharmaceutical Market Leadership An active
pharmaceutical ingredient (API) is a drug or a
combination of drugs used in finished
pharmaceutical products (FPP) intended for the
diagnosis, treatment, or prevention of diseases.
API is the component of any drug that produces
the intended effects. Some drugs, such as
combination therapies, have multiple active
ingredients to treat different symptoms or act in
different ways. Production of APIs has
conventionally been done by pharmaceutical
companies in their home countries however, in
recent years, many companies have chosen to send
manufacturing overseas with an aim to cut costs.
This has caused major changes in how these drugs
are regulated, with more stringent guidelines
and inspections put into place. 360Quadrants, the
most granular comparison platform, has released a
quadrant on the Active Pharmaceutical Ingredient
Market to help businesses make quicker and more
informed decisions. The quadrant has Pfizer,
Roche, and Sanofi sharing space as Visionary
Leaders. 360Quadrants are generated Active
Pharmaceutical Ingredient Leaders Like product
maturity and company maturity. Quadrants will be
updated every three months based on market and
regional analyses and developments in the Active
Pharmaceutical Ingredient Market. 360Quadrants
also lists the 20 best companies in the Active
Pharmaceutical Ingredient Market space. Get
Sample PDF (including COVID19 Impact Analysis) of
Market Report _at_ https//www.360quadrants.com/quadr
ant-report/active-pharmaceutical-ingredient-(api)/
buy- now?reporttypecorporates_license_price CA
TEGORIZATION OF ACTIVE PHARMACEUTICAL INGREDIENT
(API) VENDORS ON 360QUADRANTS 30 companies
offering Active Pharmaceutical Ingredients were
analyzed, of which 20 Top Active Pharmaceutical
Ingredient companies were shortlisted and
categorized on a quadrant under Visionary
Leaders, Innovators, Dynamic Differentiators, and
Emerging Leaders. Pfizer, Roche, Sanofi,
Novartis, AbbVie, GlaxoSmithKline, Gilead
Sciences, Merck Co, Eli Lilly, Johnson
Johnson, AstraZeneca, Celgene, and Boehringer
Ingelheim have been identified as Visionary
Leaders,as they have established product
portfolios and a robust market presence
business strategy. Teva, Allergen, Amgen, and
Bristol-Myers Squibb have been identified as
Innovators, as they have focused product
portfolios but mediocre business strategies. Novo
Nordisk, Mylan, and Biogen Idec have been
recognized as Dynamic Differentiators, as they
have strong business strategies but weaker
product offerings as compared to other market
players. These companies are known to focus on
specific product offerings, as opposed to having
elaborate portfolios. Takeda, Daiichi Sankyo,
Shire, and Astellas have been identified as
Emerging Companies, as they have niche product
offerings but poor business strategies. 360Quadran
ts conducts an in-depth SWOT analysis and
accurately analyzes the companies considered for
evaluation. This helps service providers learn
about new opportunities and areas where they lag
behind their peers. It also helps clients choose
the most appropriate vendors for their
2
requirements. GlaxoSmithKline (UK) is one of the
key players in the global API market. The
Pharmaceuticals segment of the company has a
broad portfolio of innovative and established
medicines. GSK focuses on research development
activities, which gives the organization a
competitive advantage. For instance, the company
invested significantly in RD activities in 2018
and 2019. Moreover, the RD activities undertaken
by the company aim at incorporating genetics and
advanced technologies. The company is involved in
the contract manufacturing of APIs in Ireland,
the UK, Singapore, and Australia. The company
primarily focuses on collaborations and
partnerships to enhance its product offerings and
maintain its position in the market. Buy
(Global) Company Evaluation Report
https//www.360quadrants.com/quadrant-report/activ
e- pharmaceutical-ingredient-(api)/buy-now?report
typecorporates_license_price
Bristol-Myers Squibb (US) is a prominent player
in the API market and holds expertise in
pharmaceutical ingredients. The company has a
broad product portfolio in biologics, which isan
important factor inits future growth, especially
in the biopharmaceuticals market. The company
invested 6.41 billion, 4.94 billion, and 5.92
billion in RD activities in the years 2017,
2016, and 2015, respectively. In order to
maintain its leadership position in the market,
the company focuses on growth strategies such as
partnerships and expansions. The company is
adopting new strategies and developing and
expanding its product range. It also focuses on
collaborations, agreements, acquisitions, and
approvals in order to meet the rising market
demand. For instance, in November
2019,Bristol-Myers Squibb acquired Celgene, C a
leading biopharma company. This acquisition
helped BMS to further progress relating to the
patent estate for REVLIMID, the US Food and Drug
Administration (FDA) approval of INREBIC
(fedratinib) for the treatment of certain forms
of myelofibrosis, the US FDA approval of REBLOZYL
(luspatercept-aamt) for the treatment of anaemia
in certain adult patients with beta thalassemia,
and regulatory filings of luspatercept and
ozanimod in the US and Europe. Eli Lilly (US) is
one of the leading players in the global API
market. The company invests significantlyin
research development in order to sustain its
competitiveness. For instance, in 2017, the
company invested USD 5.3 billion in RD
activities. Through Kinsale Manufacturing, it
develops, manufactures, and supplies APIs. The
company manufactures small molecule APIs along
with APIs for biopharmaceutical medicines. Eli
Lillys human pharmaceutical research focuses on
cancer, diabetes, neurodegeneration, immunology,
and pain. In order to influence growth
opportunities in the global API market, the
company emphasizes on adopting organic as well
as inorganic growth strategies. For example, in
February 2020, Eli Lilly completedthe
acquisition of Dermira, a leading
biopharmaceutical company specializing in
dermatology. This acquisitionenables the
expansion of Lilly's portfolio of marketed
dermatology medicines with the addition of
QBREXZA (glycopyrronium), a medicated cloth
approved by the FDA for the topical treatment of
primary axillary hyperhidrosis (uncontrolled
excessive underarm sweating).
3
Buy Active Pharmaceutical Ingredient Competitive e
valuation Report https//www.360quadrants.com/qua
drant-report/active-pharmaceutical-ingredient-(api
)/buy- now?reporttypecorporates_license_price

• 360QUADRANTS COMPANY EVALUATION METHODOLOGY
• The top Active Pharmaceutical Ingredient
  Competitive evaluation performed using the
  following methodology
• A highly experienced team of researchers and
  senior analysts conducts extensive research to
  generate a list of vendors (competitors).
• A patent-pending algorithm is used to collect
  inputs from key stakeholdersindustry
• experts, buyers, vendors, and 360Quadrants
  analystsbased on criteria for Product Maturity
  and Company Maturity.
• Criteria under Product Maturity include breadth
  and depth of product/service offering, product
  features and functionalities, product
  differentiation, and their impact on customer
  value.
• Criteria under Company Maturity include
  geographical footprint, partner ecosystem,
  financial stability, and client coverage or
  sector footprint.
• Approximately 30 in-depth parameters will be
  considered for research into the Active
• Pharmaceutical Ingredient market. These
  parameters will be updated every six months to
  ensure the latest developments are taken into
  consideration.
• A weight is assigned to each stakeholder based on
  information gathered pertaining to the above
  criteria as well as inputs from stakeholders.
  These inputs follow the order of priority given
  below
• Buyers
• Industry Experts
• 360Quadrants Analysts
• Vendors (Competitors)
• The inputs are analyzed, and a final rating is
  assigned to each vendor (competitor).
• After the finalization of ratings, each vendor is
  placed in the most relevant quadrant based on
  its score.
• ABOUT 360QUADRANTS
• 360Quadrants is the largest marketplace looking
  to disrupt US 6.3 trillion of technology spends
  and is the only rating platform for vendors in
  the technology space. The platform provides users
  access to unbiased information that helps them
  make qualified business decisions. The platform
  facilitates deeper insight using direct
  engagement with 650 industry experts and
  analysts and allows buyers to discuss their
  requirements with 7500 vendors. Companies get to
  win ideal new customers, customize their
  quadrants, decide key parameters, and position
  themselves strategically in a niche space, to be
  consumed by giants and startups alike. Experts
  get to grow their brand and increase their
  thought leadership. The platform targets the
  building of a social network that links industry
  experts with companies worldwide. The platform
  has around 400 total buyers across various
  markets.

4
360Quadrants will also be launching quadrants in
fields like Digital Transformation Software,
Cloud Computing Software, and Access Control
Software. Access Full Report
_at_- https//www.360quadrants.com/quadrant-report/a
ctive-pharmaceutical- ingredient-(api)/buy-now?re
porttypecorporates_license_price